DNB Healthcare Prize 2017

healthcare
As a leading Nordic Healthcare bank, DNB want to contribute to an industry in growth in Norway and has established a healthcare prize for early-stage healthcare companies within pharmaceuticals, biotech, medtech and diagnostics.

The finalists for the DNB Healthcare Prize 2016

For the second year in a row, the DNB Healthcare Prize will be presented at the DNB Nordic Healthcare Conference 15 December.Six finalists will present and compete for the prize of NOK 1 million. DNB’s CEO Rune Bjerke will announce the winner of the DNB Nordic Healthcare Prize 2016. The finalists for the DNB Healthcare Prize:

  1. SpinChip Diagnostics AS (www.spinchip.no)
  2. Vectron Biosolutions AS (www.vectronbiosolutions.com)
  3. Otivio AS (www.otivio.com)
  4. Prediktor Medical AS (www.prediktormedical.com)
  5. EpiGuard AS (www.epiguard.com)
  6. Oncoinvent AS (www.oncoinvent.com)
DNB Healthcare Prize is a part of DNB Nordic Healthcare Conference.
» Read more aboute the conference and register

Who can apply?

Norwegian companies within:  
• Pharmaceuticals
• Biotech
• Diagnostics
• Medtech
• eHealth

The company must be in a development phase and cannot be listed on a stock exchange. Companies engaged in nutrition, animals, marine technology, care services and hospital administration do not meet the application criteria.

What are the winning criteria?
Participating companies will be evaluated based on their innovation capacity, business potential and an ability to execute their strategy. In the semi-final and final, the companies are also judged on how they present and communicate their business case to the jury and investors.

Application deadline and process:

The deadline for applying was 26 October 2016.

17 November – semi-final
• Semi-final at Oslo Cancer Cluster Incubator.
• Six-minute pitch/investor presentation to a jury.

7 and 8 December – course in presentation skills
• Training in presentation skills by Ergo Ego.

15 December - final
• Training in presentation skills before the final.
• Six-minute pitch/investor presentation to a jury and an audience.
• Final and presentation of the DNB Healthcare Prize 2016 by Rune Bjerke, CEO, at DNB’s headquarters in Bjørvika, Oslo.
 

The jury

•    Espen Tidemann Jørgensen, Portfolio Manager, Holta Invest
•    Anders Tuv, Investment Director, Norwegian Radium Hospital Research Foundation
•    Alexander Woxen, Founding Partner of StartupLab Oslo, Kubikam
•    Ingrid Akay Teigland, Hadean Ventures
•    Benedicte Bakke, Senior Advisor, DNB Healthcare
 

Why is this a good opportunity?

The winner of the DNB Healthcare Prize will receive recognition and prize money of NOK 1 million to help in an early growth phase. Participants who reach the semi-final will hold a presentation for potential investors and the jury. The six finalists will receive professional training in presentation skills and present their company to a large audience.

We want to help more companies succeed
Healthcare is a sector with considerable growth potential and many companies in Norway have what it takes to succeed. DNB wishes to contribute long term to ensure that healthcare continues to grow as an industry in Norway.

DNB International Healthcare
We are the leading healthcare bank and among the largest healthcare banks in the United States. DNB International Healthcare has a portfolio with more than 50 international companies within pharmaceuticals, biotech, medtech and diagnostics.

 

Contact information

  • Terje Straume, Head DNB International Healthcare, Send email
  • Jon Båsen Andersen, Senior Vice President International Healthcare, Send email
  • Benedicte Bakke, International Healthcare, Send email

Our business partners

Logo Oslo
Logo Oslo
Logo Oslo
Logo Oslo Cancer Cluster
 
Logo Oslo